Treatment of multiple myeloma with<unk>  potentially increases the patient's susceptibility to bacterial and viral infections, due to the killing of natural killer cells (which are the main innate immune system defense against virus).<unk>  frequently causes human cytomegalovirus (CMV) reactivation by an unknown mechanism. Injection related reactions (inflammation-like) are also common.
Daratumumab
Lanadelumab
Ofatumumab
Alirocumab
Tralokinumab
Olaratumab
Evinacumab
Ustekinumab